GI & Endoscopy

  Five must read articles for gastronterologists this week:

Exact Sciences' multitarget stool DNA test, Cologuard, is divisive. Touting 92 percent sensitivity and 87 percent specificity rates for detecting all stages of colorectal cancer, the test is heavily marketed and has seen significant growth recently. 

The U.S. Multi-Society Task Force on Colorectal Cancer updated its 2012 recommendations for postcolonoscopy follow-up with or without polypectomy, according to an article in Gastroenterology Consultant.

Here are four GI leaders who have joined new organizations in the past year:

Three gastroenterologists making headlines this week:

Affiliates of Apollo Global Management will acquire Covis Pharma BV from Cerberus Capital Management, with a planned closing date in the first quarter of 2020.

Nonalcoholic steatohepatitis is a 21st century epidemic that has no simple diagnostic tool or treatment, Medscape reports.

Three gastroenterology leaders to know this week:

The Endoscopy Center of WNY in Williamsville, N.Y, is changing ownership, according to Buffalo Business First.

Two leading gastroenterologists debated colorectal cancer screening at the 2020 Gastrointestinal Cancers Symposium, Jan. 23-25 in San Francisco, as reported by Targeted Oncology.